OMN6 – the Next-Generation of Antibiotic Drugs

OMN6 is a novel antimicrobial peptide developed for IV administration in hospitalized patients suffering from severe or life-threatening infections involving Multi-Drug-Resistant bacteria

OMN6 is effective and safe. Targeting a huge, urgent unmet need, OMN6 eliminates resistan

  • Infection prevention
  • Antimicrobial compounds
  • Alternative antimicrobials
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Fungi
  • Yeasts
  • Viruses
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Joint Venture
  • Sell
  • Outsource

Funding organisation:

    Infectious disease area:

      Geographic origin:

        Big-pharma or a strategic-player that has the experience and expertise to join us in bringing a life-saving antibiotic drug to the market

        Omnix Medical is a privately-owned biotechnology company developing the next-generation antibiotics against Multi Drug Resistant bacteria

        Omnix is developing a pipeline of anti-infective compounds at different stages of the development route

        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!